title: The treatment of psoriatic arthritis.
abstract: Psoriatic arthritis (PsA) is a chronic, autoimmune, seronegative inflammatory arthritis characterized by varying degrees of axial and peripheral arthritis. Here, we review the literature on the pharmacological management of PsA and present a simple treatment algorithm based on the available information. Although PsA management must be individualized to the degree and type of joint pain and inflammation, in general, nonsteroidal antiinflammatory drugs (NSAIDs) still represent first-line treatment of mild PsA. Second-line therapy includes older agents such as gold salts, methotrexate, sulfasalazine, and cyclosporine. The tumor necrosis factor alpha (TNF-alpha) antagonists represent the most recent major advance in the clinical management of PsA.
authors.affiliation: Rush University Medical Center and John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois 60612, USA. amanadan@rush.edu
authors.forename: Augustine M
authors.initials: AM
authors.lastname: Manadan
authors.forename: Winston
authors.initials: W
authors.lastname: Sequeira
authors.forename: Joel A
authors.initials: JA
authors.lastname: Block
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha